CellSource to Acquire Medibase as Unit; Shares Down 6%
CellSource (TYO:4880), specializing in regenerative medicine, will acquire Medibase to integrate its cloud-based electronic medical record services, according to a Thursday filing on the Tokyo Stock Exchange.
Effective Sept. 12, the acquisition aims to develop CellSource's operations in regenerative medicine and explore new business opportunities in cosmetic surgery and dermatology.
The transaction is expected to have a minor impact on CellSource's current fiscal performance but should benefit long-term growth.
Shares of the company were down 6% in recent trade.
Price (JPY): $1296.00, Change: $-85, Percent Change: -6.15%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.